Literature DB >> 8390369

Effect of pretreatment with the selective beta 1-adrenoceptor antagonist bisoprolol on the subsequent cardiovascular actions and beta-adrenoceptor subtype specific occupancy of celiprolol in healthy man.

C de Mey1, K Beithaupt, D Palm, U Fuhr, G G Belz.   

Abstract

The cardiovascular effects at rest and during exercise and beta 1- and beta 2-adrenoceptor occupancy following a single dose of 1200 mg celiprolol p.o. were investigated in 8 healthy subjects with or without pretreatment with a single dose of 20 mg bisoprolol p.o., using a placebo-controlled, 2-way cross-over design. The ergometric responses of heart rate (HR) and systolic blood pressure (SBP) after celiprolol were reduced to a similar extent as after bisoprolol, but the cardiovascular function at rest was affected in a different way: there was a rise in HR, clear enhancement of cardiac systolic performance, and a considerable drop in the estimated total peripheral vascular resistance, associated with median beta 1-RRA and beta 2-RRA occupancies of 88 and 34%, respectively. The cardiovascular effects of celiprolol were not affected by pretreatment with bisoprolol. Celiprolol thus binds extensively to beta 1-adrenoceptors, moderately to beta 2-adrenoceptors, acts as beta 1-adrenergic antagonist (exemplified by the ergometric effects) but has vasodilator, positive chronotropic and cardiac systolic performance enhancing properties, which do not involve either direct or indirect beta 1-adrenergic agonism, but which might reflect beta 2-adrenergic agonism.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8390369     DOI: 10.1007/bf00316470

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  38 in total

1.  Agreement and reproducibility of the estimates of cardiovascular function by impedance cardiography and M-mode echocardiography in healthy subjects.

Authors:  C de Mey; J Matthews; R Butzer; V Schroeter; G G Belz
Journal:  Br J Clin Pharmacol       Date:  1992-07       Impact factor: 4.335

2.  Dose-response following single administrations of a new cardiac performance enhancer RO 13-6438 in normal volunteers.

Authors:  G G Belz; H C Stern; R Butzer
Journal:  J Cardiovasc Pharmacol       Date:  1985 Jan-Feb       Impact factor: 3.105

3.  No evidence for a direct vasodilatory effect of celiprolol on human vasculature in vivo or in vitro.

Authors:  A Hughes; G Martin; P Goldberg; S Thom; P Sever
Journal:  J Cardiovasc Pharmacol       Date:  1987-11       Impact factor: 3.105

4.  Comparison of the acute hemodynamic effects of intravenous celiprolol and propranolol in patients with suspected coronary disease.

Authors:  G Gensini; C Dator; P Esente; F S Caruso; T Solomon
Journal:  J Cardiovasc Pharmacol       Date:  1986       Impact factor: 3.105

5.  Properties of agonist binding at the beta-adrenoceptor of the rat reticulocyte.

Authors:  G Wiemer; A Wellstein; D Palm; H M von Hattingberg; D Brockmeier
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1982-10       Impact factor: 3.000

Review 6.  The central and peripheral hemodynamics of celiprolol.

Authors:  G Mancia
Journal:  Am Heart J       Date:  1988-11       Impact factor: 4.749

7.  Celiprolol has no direct or indirect relaxing effects in isolated arteries and veins.

Authors:  S T O'Rourke; P M Vanhoutte
Journal:  J Cardiovasc Pharmacol       Date:  1990-05       Impact factor: 3.105

8.  Time course and nature of postprandial haemodynamic changes in normal man.

Authors:  C de Mey; S Hansen-Schmidt; D Enterling; I Meineke
Journal:  Clin Physiol       Date:  1989-02

9.  Effect of celiprolol on large and small arteries of the forearm circulation in hypertensive patients.

Authors:  O Roman; N Meza; C Klenner
Journal:  Cardiovasc Drugs Ther       Date:  1990-06       Impact factor: 3.727

10.  Effects of celiprolol (REV 5320), a new cardioselective beta-adrenoceptor antagonist, on in vitro adenylate cyclase, alpha- and beta-adrenergic receptor binding and lipolysis.

Authors:  R G Van Inwegen; A Khandwala; I Weinryb; T P Pruss; E Neiss; C A Sutherland
Journal:  Arch Int Pharmacodyn Ther       Date:  1984-11
View more
  4 in total

1.  Reproducibility and consistency of the responses to supine bicycle ergometry; evaluation in conjunction with beta 1-adrenoceptor occupancies.

Authors:  C De Mey; K Breithaupt-Grögler; J Schloos; D Palm; G G Belz
Journal:  Br J Clin Pharmacol       Date:  1994-11       Impact factor: 4.335

2.  Method specificity of the auscultatory estimates of the inodilatory reduction of diastolic blood pressure based on Korotkoff IV and V criteria.

Authors:  C De Mey
Journal:  Br J Clin Pharmacol       Date:  1995-05       Impact factor: 4.335

3.  Beta 2-adrenoceptor-mediated intrinsic sympathomimetic activity of carteolol: an in vivo study.

Authors:  Heike Bruck; Ulrike Poller; Hendrik Lüssenhop; Klaus Pönicke; Thomas Temme; Gerd Heusch; Thomas Philipp; Otto-Erich Brodde
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-10-23       Impact factor: 3.000

Review 4.  Celiprolol. An evaluation of its pharmacological properties and clinical efficacy in the management of hypertension and angina pectoris.

Authors:  C J Dunn; C M Spencer
Journal:  Drugs Aging       Date:  1995-11       Impact factor: 3.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.